{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:42:30Z","timestamp":1762850550453,"version":"build-2065373602"},"reference-count":18,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15288","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:31:59Z","timestamp":1758544319000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of combined immunotherapy and chemotherapy in recurrent non\u2011small cell lung cancer during durvalumab maintenance therapy: A case report"],"prefix":"10.3892","volume":"30","author":[{"given":"Yuki","family":"Maze","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Mitsumura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nakahama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Nei","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Hanada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Uruga","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Fuji","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyo","family":"Tamaoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105\u20118470, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"key20251111103747_b1-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"723","DOI":"10.7326\/0003-4819-125-9-199611010-00003","article-title":"Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A mata-anaysis","volume":"125","author":"Pritchard","year":"1996","journal-title":"Ann Intern Med"},{"key":"key20251111103747_b2-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/1097-0142(19950815)76:4<593::AID-CNCR2820760409>3.0.CO;2-N","article-title":"Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis","volume":"76","author":"Marino","year":"1995","journal-title":"Cancer"},{"key":"key20251111103747_b3-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"key20251111103747_b4-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"key20251111103747_b5-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/JTO.0b013e3181753b38","article-title":"Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III Non-small cell lung cancer","volume":"3","author":"Naito","year":"2008","journal-title":"J Thorac Oncol"},{"key":"key20251111103747_b6-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20251111103747_b7-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1200\/JCO.2009.24.5050","article-title":"Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20251111103747_b8-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41416-018-0243-2","article-title":"A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L","volume":"119","author":"Sasaki","year":"2018","journal-title":"Br J Cancer"},{"key":"key20251111103747_b9-ol-30-6-15288","first-page":"675","article-title":"Comparison of vinorelbine plus cisplatin and s-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III Non-small Cell lung cancer","volume":"32","author":"Shukuya","year":"2012","journal-title":"Anticancer Res"},{"key":"key20251111103747_b10-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20251111103747_b11-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"866542","DOI":"10.3389\/fonc.2022.866542","article-title":"Radiosurgery for five to fifteen brain metastases: A single centre experience and a review of the literature","volume":"12","author":"Rogers","year":"2022","journal-title":"Front Oncol"},{"key":"key20251111103747_b12-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3171\/2017.11.JNS171500","article-title":"Global neurosurgery: The current capacity and deficit in the provision of essential neurosurgical care. Executive summary of the global neurosurgery initiative at the program in global surgery and social change","volume":"130","author":"Dewan","year":"2018","journal-title":"J Neurosurg"},{"key":"key20251111103747_b13-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20251111103747_b14-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00280-023-04547-2","article-title":"Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: A multicenter retrospective analysis (TOPGAN 2021-02)","volume":"92","author":"Hasegawa","year":"2023","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20251111103747_b15-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: A multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20251111103747_b16-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"},{"key":"key20251111103747_b17-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20251111103747_b18-ol-30-6-15288","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/j.ijrobp.2021.07.1208","article-title":"Pulmonary hemorrhage in patients treated with thoracic stereotactic ablative radiotherapy and anti-angiogenic agents","volume":"111","author":"Lau","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:37:51Z","timestamp":1762850271000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15288","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}